Thyme Care Raises $125M Series E, Valued at Over $2B
Nashville, Tenn. – September 07, 2026 -- Thyme Care has closed a Series E financing round exceeding $125 million at a valuation of more than $2 billion, led by Morgan Health with participation from Humana and CVS Health Ventures.
Strategic payers back oncology care model managing $7 billion in spend
The round drew institutional backers including AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health. Thyme Care services now reach more than 10.5 million people across all 50 states, and the company manages over $7 billion in oncology spend. The care model delivers validated reductions of 5 to 10 percent in total cost of care, according to the company, which reports it is profitable and generates positive free cash flow.